UP govt allows phase-III trial of Covaxin in Lucknow and Gorakhpur

The Uttar Pradesh Government on Wednesday allowed the phase-3 trial of anti-COVID-19 vaccine ''Covaxin'' in Lucknow and Gorakhpur.

The vaccine is currently being tested by Bharat Biotech Ltd in collaboration with the Indian Council of Medical Research (ICMR).

Additional Chief Secretary (Medical and Health) Amit Mohan Prasad conveyed the government's permission to test the anti-COVID-19 vaccine in the two cities through a letter to Bharat Biotech International Limited's director V Krishna Mohan.

"Kindly refer to your letter dated September 19, 2020 for permission and facilitation to initiate the COVAXIN Phase 3 Efficacy and Safety clinical trials in Uttar Pradesh. It has been decided to allow Bharat Biotech to conduct Phase-3 trial in Lucknow and Gorakhpur," Prasad said in his letter.

"All permission will have to be obtained by you and all safety and other protocols will have to be followed as per the guidelines of the Government of India for conducting clinical trials," he added in the letter.

For Lucknow, Dr R K Dhiman, the director of Sanjay Gandhi Post Graduate Institute of Medical Sciences has been made the nodal person, while for Gorakhpur, Dr Ganesh Kumar, the Principal of BRD Medical College has been made the nodal officer.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel